Treatment response to daratumumab in antibody-mediated kidney allograft rejection: evidence from serial protocol biopsies
Nele Kirsten Kanzelmeyer, Murielle Verboom, Michael Hallensleben, Christina Bade-Döding, Anne Schön, Dieter Haffner, Jan Hinrich Bräsen, Anette Melk · 2026
Read Treatment response to daratumumab in antibody-mediated kidney allograft rejection: evidence from serial protocol biopsies by Nele Kirsten Kanzelmeyer, Murielle Verboom, Michael Hallensleben, Christina Bade-Döding, Anne Schön, Dieter Haffner, Jan Hinrich Bräsen, Anette Melk (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13437070.txt.
Description
Nele Kirsten Kanzelmeyer and colleagues report two children whose transplanted kidneys faced stubborn antibody attack, treated with daratumumab, a drug aimed at CD38 on immune cells. Published in 2026, their case report follows a ten-year-old girl and a nine-year-old boy after kidney transplant. Repeat tissue samples let the team watch the grafts heal or worsen.
Both children first received five weekly doses, then further doses every two to four weeks. In the girl, active rejection faded into mostly chronic change, with far less vessel inflammation and a turned-negative tissue stain. The boy first showed more chronic damage, then full clearing of active disease and a sharp drop in protein in his urine. Harmful donor antibodies fell in both, graft function steadied, and no serious side effects appeared. The authors call for controlled trials to settle dose and safety in children.
Catalog record
| CREATOR | Nele Kirsten Kanzelmeyer, Murielle Verboom, Michael Hallensleben, Christina Bade-Döding, Anne Schön, Dieter Haffner, Jan Hinrich Bräsen, Anette Melk |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 40400 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |